Laurentiu Vlad resigned as Class III director and audit committee member effective March 16, 2023, citing personal reasons; no disagreement with the company.
Jean-Manassé Theagène elected as Class III director to fill the vacancy, effective March 17, 2023, until the 2025 annual meeting.
Stan Smith appointed to the audit committee on March 16, 2023, filling the vacancy from Vlad's resignation.
Theagène will receive standard independent director compensation and enter into an indemnification agreement with the company.
On March 17, 2023, upon the recommendation of the Nominating and Corporate Governance Committee (the “Nominating Committee”) of the Board, the Board elected Jean-Manassé Theagène to serve as a Class III director of the Board, with immediate effect, until the Company’s 2025 annual meeting of stockholders, or until such time as he resigns or is removed, and his successor has been elected and qualified.
On March 13, 2023, Laurentiu Vlad notified MAIA Biotechnology, Inc. (the “Company”) that he is resigning from the Board of Directors (the “Board”) of the Company effective on March 16, 2023, due to personal reasons.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
Jean-Manassé Theagène was elected as Class III Director at MAIA Biotechnology, Inc..
Action
elected
Role
Class III Director
Exact text from the filing
On March 17, 2023, upon the recommendation of the Nominating and Corporate Governance Committee (the “Nominating Committee”) of the Board, the Board elected Jean-Manassé Theagène to serve as a Class III director of the Board, with immediate effect, until the Company’s 2025 annual meeting of stockholders, or until such time as he resigns or is removed, and his successor has been elected and qualified.
Laurentiu Vlad resigned as Class III Director and Audit Committee Member at MAIA Biotechnology, Inc..
Action
resigned
Role
Class III Director and Audit Committee Member
Exact text from the filing
On March 13, 2023, Laurentiu Vlad notified MAIA Biotechnology, Inc. (the “Company”) that he is resigning from the Board of Directors (the “Board”) of the Company effective on March 16, 2023, due to personal reasons.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.